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Abstract – There is a long-standing polemic concerning the usefulness of antidepressants in the treatment of major depres-
sive disorder. In this paper we propose to highlight some aspects of this controversy by exploring the mutual inﬂuence of
psychopharmacology and trial methodologies. Indeed, antidepressant eﬃcacy, if not proved, was accepted before antide-
pressant randomised controlled trials (RCTs) were run. While RCTs became a gold standard to meet the requirements of
the regulatory bodies, methodological tools were required to measure outcomes and to test whether antidepressants provide
statistically signiﬁcant beneﬁts as compared with a placebo. All these methodological options have nonetheless introduced
fuzziness in our interpretation of study results, in terms of clinical meaningfulness and in terms of transposability to a real
life settings. Additionally, selective publication raises concerns about the published literature, and results in many paradoxes.
Instead of providing easy answers, the application of the RCT paradigm in MDD raises numerous questions. This is probably
in the nature of all scientiﬁc studies, but it can be in contradiction with clinicians’ expectations, who want to be sure that the
treatment will (or will not) work for their individual patients.
Mots clés :
antidépresseurs ;
essais randomisés
contrôlés ;
placebo ;
biais de publication ;
critères de jugements
Résumé – Comprendre le débat sur les antidépresseurs dans le traitement de l’épisode dépressif majeur. Il existe
un vieux débat à propos de l’utilité des antidépresseurs dans le traitement de l’épisode dépressif majeur. Dans cet article,
nous présentons certains aspects de la controverse en explorant l’inﬂuence mutuelle de la psychopharmacologie et de la
méthodologie des essais. En eﬀet, l’eﬃcacité des antidépresseurs était, sinon prouvée, admise avant que les premières études
contrôlées randomisées (ECR) ne soient conduites. Alors que les ECR devenaient, du point de vue des autorités sanitaires,
le “gold standard” pour l’évaluation des médicaments, il devenait nécessaire d’adopter des outils méthodologiques per-
mettant de mesurer des critères de jugement et de tester si les antidépresseurs permettaient l’obtention d’une diﬀérence
statistiquement signiﬁcative par rapport au placebo. Ces options méthodologiques ont néanmoins introduit du ﬂou quand à
l’interprétation des résultats des ECR, notamment en terme de signiﬁcativité clinique et de transposabilité « à la vraie vie ».
Au-delà, la publication sélective des ECR impacte la validité de la littérature publiée et résulte en de nombreux paradoxes.
Ainsi, au lieu de fournir des réponses simples, l’application du paradigme de l’ECR à l’épisode dépressif majeur soulève
de nombreuses questions. Il en va probablement de même pour toutes les études scientiﬁques, mais dans ce cas précis, cela
rentre en contradiction avec les attentes des cliniciens qui veulent être sûr que leur traitement sera eﬃcace (ou pas) pour
leurs patients.
Abbreviations : see end of article.
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1. Introduction1
There is a long-standing but still active polemic concerning2
the usefulness of antidepressants in the treatment of major de-3
pressive disorder. Recently, some opinion leaders stated that an-4
tidepressants have no place in evidence-based medicine, [1] while5
others consider that this is an “irrational polemic” and have dis-6
puted psychological interventions for depression. [2] This debate7
could lead to a major public health problem, since treatments that8
are oﬀered to patients (pharmacological or psychological) are be-9
ing discredited by partisans of either side, and this risks depriving10
some patients with depression of useful treatments. The subject11
is too important to reduce to a mere opposition between “pro”12
and “anti” antidepressants; [3] and it deserves careful examination13
from diﬀerent points of view. In this paper we propose to highlight14
some aspects of this controversy.15
2. Birth of the concepts of antidepressant16
and major depressive disorder17
In the case of depression, stimulants were used as the treat-18
ment during the 1940s. In the 1950s, new substances such as ipro-19
niazid and imipramine were viewed as speciﬁc to treating depres-20
sion, whereas earlier stimulants were regarded as non-speciﬁc. [4]21
In 1958, Khun[5] presented imipramine as an antidepressant al-22
though its biological foundations were not established. He noted23
that “best responses were obtained in cases of endogenous de-24
pression showing the typical symptoms of mental and motor re-25
tardation, fatigue, feeling of heaviness, hopelessness, guilt, and26
despair” and that this “condition is furthermore characterized by27
the aggravation of symptoms in the morning with a tendency to28
improvement during the day”. Promptly, the monoamine theory29
of depression emerged[6] with the work by Sigg[7] who demon-30
strated that imipramine can potentiate the eﬀects of noradrenaline,31
by Burn and Rand[8] who described the uptake of noradrenaline32
by adrenergic nerves, by Marshall et al. [9] who reported that33
imipramine blocked the uptake of serotonin by platelets, by Ax-34
elrod et al. [10] who described the uptake of labelled noradrenaline35
by adrenergic nerves which could be blocked by imipramine, and36
by Dengler et al. [11] who reported similar data regarding nora-37
drenaline uptake by brain tissue. Arvid Carlsson developed zime-38
lidine, a new treatment blocking the uptake of serotonin with-39
out blocking the uptake of cathecholamines. [12] While zilmelidine40
had a very favourable safety proﬁle, within a year and a half of41
its introduction, some case reports of Guillain-Barré syndrome42
emerged, apparently caused by the drug, prompting its manu-43
facturer to withdraw it from the market. After its withdrawal,44
it was succeeded by ﬂuoxetine and the other serotonin reuptake45
inhibitors (SRIs) which were considered as selective drugs with 46
fewer adverse events. [13] 47
The idea of an antidepressant, and the discoveries about their 48
putative biological properties, reshaped the concept of depres- 49
sion. A debate emerged concerning whether there was any value 50
in distinguishing “endogenous depression” and milder conditions 51
in relation with stressful events known as neurotic depression 52
(the Khun perspective) and treating them diﬀerently, or whether 53
there was no basis for separate categories of depression since they 54
all lie on a continuum of severity, as proposed by Akiskal and 55
Mc Kinney. [14] In 1980, the Diagnostic and Statistical Manual of 56
Mental Disorders (DSM) III [15] retained the latter view by com- 57
bining the two entities under the label of major depressive disor- 58
der (MDD). 59
Non-scientiﬁc reasons have probably also contributed to the 60
wide acceptation of the concepts of antidepressant and MDD.[4] 61
Concerning the ideological conﬂict of interest, these concepts 62
were not in favour of the psychiatric profession’s desire to inte- 63
grate with general medicine and to counter attacks from the an- 64
tipsychiatry movement. Concerning the ﬁnancial conﬂict of inter- 65
est, the pharmaceutical industry also had an interest in promoting 66
these concepts. [4] 67
3. RCTs became inescapable in the evaluation 68
of antidepressants 69
Alongside these conceptual changes randomized controlled 70
trials (RCTs) developed in the evaluation of medication. The Med- 71
ical Research Council (MRC) ran the ﬁrst RCT versus placebo in 72
1948 to explore the eﬃcacy of streptomycin in tuberculosis. [16] 73
Previous non-randomized studies had established that strepto- 74
mycin worked in the short term treatment of tuberculosis, but an a 75
posteriori interpretation of this trial is that it probably proved the 76
“eﬃcacy of RCTs” rather than the eﬃcacy of streptomycin. [17] In 77
the years following this trial, many RCTs were funded by national 78
public bodies, for example the MRC evaluation of imipramine 79
versus phenelzine, electroconvulsive therapy and placebo in the 80
relief of depressive illness. [18] These trials were often concerned 81
with broad questions regarding classes of treatments, rather than 82
speciﬁc compounds. [19] 83
After the thalidomide crisis in 1962, the Kefauver-Harris drug 84
amendments were passed to ensure drug eﬃcacy and greater drug 85
safety. It was because medications entailed a risk that evidence 86
of eﬃcacy was sought and, for the ﬁrst time, drug manufactur- 87
ers were required to prove to the Food and Drug Administra- 88
tion (FDA) the eﬃcacy of their products before marketing them. 89
Gradually, the situation changed, public funding declined and the 90
vast majority of clinical trials on drug treatments in psychiatry 91
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Understanding the Antidepressant Debate 3
were sponsored and conducted by the pharmaceutical industry,1
the number of trials increased dramatically, trials concerned single2
patented compounds and were designed to meet the requirements3
of the regulatory bodies. [19] While for a large proportion of med-4
ical interventions, few or no clinical trials are ever conducted, for5
antidepressants there are probably now well over a thousand. [20]6
4. The mutual inﬂuence7
of psychopharmacology and trial8
methodology9
Nonetheless, it should be noted that antidepressant eﬃcacy,10
if not proved, was accepted before antidepressant RCTs were run,11
and that no antidepressant in the RCT era was proved to be supe-12
rior to imipramine in terms of eﬃcacy. [21] Thus, being thought-13
provocative, one can say that antidepressants have made advances14
in methodology possible, rather than stating that methodology has15
enabled major advances in psychopharmacology for MDD. In-16
deed, when RCTs became a gold standard, it became necessary for17
them to take into account the particular features of psychopharma-18
cology, and especially those relating to MDD, for instance paying19
particular attention to inclusion criteria and outcomes. Concern-20
ing inclusion criteria, as it became necessary to accept a com-21
mon deﬁnition of MDD, the DSM viewpoint was reinforced as22
a standard. It also became necessary to adopt measurable, rele-23
vant and consensual outcomes providing a sensitive and accurate24
estimate of change occurring with antidepressants. [22] The Hamil-25
ton Depression Rating Scale (HDRS), developed in 1960, [23] was26
progressively imposed as a standard, and was subsequently chal-27
lenged by the Montgomery and Åsberg Depression Rating Scale28
(MADRS), [22] a scale developed to be particularly sensitive to29
treatment eﬀects. It is nonetheless interesting that a scale that is to30
be used to assess the diﬀerence between a treatment and a placebo31
was developed to be particularly sensitive to speciﬁc changes oc-32
curring under treatment. The Clinical Global Impression[24] (CGI)33
which rates severity on a scale of 1 to 7, was retained as a refer-34
ence for global assessment and some self-administered question-35
naires like the Beck Depression Inventory (BDI) among others36
were popularised by the wide development of RCTs in MDD.[25]37
Binary outcomes also had to be adopted, such as response and re-38
mission, which have meaning for clinicians. Despite the fact that39
they are intuitive, their deﬁnition is not straightforward and a con-40
sensus emerged to derive these outcomes from continuous rating41
scales by calculating the proportion of people who fall below pre-42
deﬁned threshold scores, which tend to be validated merely by43
convention and tradition. [26] Since 1991[27] remission is deﬁned44
as a score 7 on the 17 items of the Hamilton Depression Rating45
Scale (HDRS-17) and response is usually deﬁned as a reduction 46
of 50% on the HDRS-17. 47
5. Statistically signiﬁcant versus clinically 48
meaningful results 49
While these methodological tools enable the measurement 50
of outcomes and test whether antidepressants provide statistically 51
signiﬁcant beneﬁts as compared with a placebo, there is a con- 52
siderable debate concerning the real meaning of the diﬀerence in 53
term of its clinical signiﬁcance. Indeed, the identiﬁcation of a min- 54
imal clinically relevant diﬀerence on a scale is not straightforward. 55
In 2004, the National Institute of Clinical Excellence[28] stated 56
that a Hamilton score diﬀerence of three points across groups 57
could be considered as clinically signiﬁcant. This threshold was 58
consistent with previous research[29] but a recent linking anal- 59
ysis provided new insight by suggesting that a slight reduction 60
on the HAMD-17 of up to 3 points corresponds to a rating of 61
“no change” as measured with the CGI. A change close to 10 62
points was linked to the “much improved” category deﬁned by 63
the CGI. [30] But these considerations on an individual level are not 64
totally transposable to group level. On the other hand, this study 65
also suggested that the commonly used measures for response (1) 66
and remission (2) in MDD trials could reasonably be considered 67
valid because they were coherent with the CGI deﬁnitions “much 68
improved” (1) and “not at all” or “borderline mentally ill” (2), 69
respectively. Bearing in mind that the CGI is not a perfect gold 70
standard, these results are very interesting. 71
6. RCTs and the dilution of efﬁcacy 72
To cope with the questions of variability and randomness, 73
randomised controlled trials (RCT) “tell stories” about average 74
patients, and the statistical inferences underpinning RCT conclu- 75
sions concern expected values of random variables. [31] This type 76
of paradigm implies that suﬃcient eﬃcacy in a subgroup of pa- 77
tients can induce an impression of eﬃcacy for the whole group, 78
providing the study is adequately powered. This “dilution” of 79
eﬃcacy can occur especially in the case of heterogeneous cate- 80
gories such as MDD. Recent meta-analyses have indeed shed new 81
light on this debate. Meta-analyses on aggregated data by Khan 82
et al. [32] and Kirsh et al. [33] suggested that the baseline severity of 83
depressive symptoms is related to clinical trial outcomes. These 84
two meta-analyses were based on FDA data (i.e. an exhaustive set 85
of studies) but were prone to an ecological fallacy[20] since they 86
were based on aggregated data. Nonetheless, their results were 87
reproduced by Fournier et al. within the framework of an indi- 88
vidual data meta-analysis. [34] This study addressed the limitations 89
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of aggregated data meta-analyses, but since personal data are dif-1
ﬁcult to collect, it was prone to publication bias. Nevertheless,2
these three meta-analyses concluded consistently that the distinc-3
tion between antidepressants and placebo is clinically meaningful4
(using the National Institute for Clinical Excellence threshold for5
clinical signiﬁcance) only for severe and very severe patients.6
Interestingly, Gibbons et al. [35] addressed the limitations of7
the preceding studies by reanalysing all intent-to-treat individual8
longitudinal data during the ﬁrst 6 weeks of treatment for major9
depressive disorder from all sponsored randomized controlled tri-10
als on ﬂuoxetine and venlafaxine. In this meta-analysis, average11
diﬀerences at 6 weeks were small and not clinically meaningful12
(2.5 HAM-D units) and baseline severity was not shown to af-13
fect symptom reduction. But these small overall mean diﬀerences14
translated into clinically signiﬁcant diﬀerences in response rates15
(estimated response rates were 58.4% for drug versus 39.9% for16
placebo) and remission rates (59.1% for drug versus 41.9% for17
placebo, relative risk = 1.5, number needed to treat = 5). This18
ﬁnding seems surprising. Intuitively, the two methods of assess-19
ing outcome should produce similar conclusions, since they are20
derived from the same data. However, this result can be explained21
by an artefact inherent in the transformation of continuous data22
into categorical data, which can magnify small diﬀerences. [36] But23
on the other hand, transformation of continuous outcomes into24
categorical outcomes implies a misclassiﬁcation bias, and mea-25
sures of association such as relative risk are likely to be biased to-26
wards 1. [37] An alternative explanation is that “eﬃcacy dilution”27
is at play here.28
7. Antidepressant alibis29
In all events, beyond any fuzziness concerning the interpreta-30
tion of antidepressant eﬃcacy in MDD, a large number of RCTs31
turn out negative. It is frequently suggested that this is due to a32
marked placebo response in antidepressant trials, which could re-33
sult from many diﬀerent factors, such as spontaneous improve-34
ment, [38] statistical regression to the mean, low level of severity35
at inclusion, co-interventions, and other biases in addition to the36
so-called placebo eﬀect. For example, spontaneous improvement37
is common in clinical practice, [38,39] and the number of follow-38
up assessments[40] is related to a signiﬁcant therapeutic eﬀect. [41]39
From a naïve point of view, one might have expected that in40
MDD, since it is a “mental disorder”, the placebo eﬀect (with41
its psychological component) might be greater than in other con-42
ditions and, as a consequence, the resulting true “pharmacologi-43
cal” eﬀect would be weaker than in general medicine. However44
the distinction is probably more subtle. [42] In a meta-analysis, [43]45
Hrobjartsson et al. identiﬁed no statistically signiﬁcant eﬀect of46
placebo interventions in depression, while a meta-analysis by 47
Kirsh et al. suggested that placebo eﬀects were considerable. [44] 48
But the RCTs included in Hrobjartsson’s meta-analysis were not 49
designed (they were underpowered) to study the placebo eﬀect 50
adequately. Similarly, in Kirsch’s meta-analysis, which comprises 51
no “untreated group” or waiting list, we cannot determine the size 52
of the placebo eﬀect. There is thus considerable debate about the 53
size, the nature and the mechanism of the placebo eﬀect in de- 54
pression. [42] For example, it has been proposed that the apparent 55
antidepressant eﬀect could be in part an active placebo eﬀect, or 56
result from bias, since side eﬀects like sexual eﬀects [45] of an- 57
tidepressants could reveal the identity of the medication to partic- 58
ipants or investigators. [46] 59
Nonetheless, while some general medical drugs have very 60
high eﬀect sizes, the eﬀect sizes obtained by psychiatric drugs are 61
in the same range as most general medical pharmaceuticals. [47] 62
Although it is diﬃcult to compare eﬀect sizes of drugs in diﬀerent 63
conditions, indications and outcomes, this ﬁnding puts the small 64
eﬀect sizes observed with antidepressants into perspective. 65
8. Overestimation and distortion of efﬁcacy 66
Antidepressants eﬃcacy is nonetheless certainly overesti- 67
mated in the published literature by selective publication and se- 68
lective outcome reporting. To explore this phenomenon, Turner 69
et al. performed an analysis of 74 studies that were submitted 70
to FDA for the approval of 12 antidepressant drugs. Among these 71
studies, the FDA considered that 38 (51%) were “positive” (with a 72
statistically signiﬁcant result on the principal outcome), 12 (16%) 73
“indeterminate” and 24 (33%) “negative” (with no statistically 74
signiﬁcant result on the principal outcome). Among the “posi- 75
tive” studies, 37 (97%) were published and only one (3%) was 76
not published. Among the “indeterminate” studies, 6 (50%) were 77
published as positive and 6 (50%) were unpublished. Finally, of 78
the “negative” studies, 3 (12%) were published as “negative”, in 79
agreement with the opinion of the FDA, 5 (21%) were published 80
as “positive”, in disagreement with the opinion of FDA and 16 81
(67%) were not published. The eﬀect size measured by perform- 82
ing a meta-analysis on the basis of published results is 0.41 with 83
a 95% conﬁdence interval of [0.36-0.45], whereas it is estimated 84
to be 0.31 with a 95% conﬁdence interval of [0.27-0.35] based on 85
all studies reported to FDA. 86
The best-documented case of selective outcome reporting 87
is probably study 329. [48–50] It was a large study of 275 de- 88
pressed adolescents conducted by SmithKline Beecham in the US 89
from 1993-1996. Its results failed to show any statistically sig- 90
niﬁcant diﬀerence between paroxetine and placebo for the two 91
primary outcomes. A GSK internal document stated that the re- 92
sults of study 329 indicated paroxetine was no more eﬀective than 93
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Understanding the Antidepressant Debate 5
placebo, and provided guidance on how to manage these disap-1
pointing results by recommending they should “eﬀectively man-2
age the dissemination of these data in order to minimize any po-3
tential negative commercial impact.” It also stated that “it would4
be commercially unacceptable to include a statement that eﬃcacy5
had not been demonstrated, as this would undermine the proﬁle6
of paroxetine.” [51] Subsequently, an article was written (or more7
precisely ghostwritten) with positive results concerning new sec-8
ondary outcome measures that had been introduced. It was con-9
cluded that paroxetine is “generally well tolerated and eﬀective10
for major depression in adolescents.” [52]11
9. Paradoxes in comparative effectiveness12
assessments13
As a result of selective outcome reporting of this type, meta-14
analyses are likely to give misleading impressions about eﬃcacy15
and comparative eﬀectiveness of antidepressants. [53,54] There is16
the case of reboxetine, a selective norepinephrine reuptake in-17
hibitor used in the treatment of depression. The previously favor-18
able risk-beneﬁt proﬁle of reboxetine shown in published trials [55]19
was reversed by the addition of unpublished data. [56] In a network20
meta-analysis performed by Cipriani et al., reboxetine was consis-21
tently shown to be worse than 11 other antidepressants, [57] includ-22
ing paroxetine which was however found in another meta-analysis23
by the same team not to have any superiority over placebo. [58] All24
in all, these meta-analyses appear paradoxical, giving the impres-25
sion that paroxetine is not superior to placebo, while it does better26
than reboxetine, which has itself been shown not to be superior27
to placebo. Additionally, although the Cipriani study found diﬀer-28
ences between antidepressants, this was not the case for another29
network meta-analysis performed by Gartlehner et al. [59]30
Another paradox has been shown in a recent paper compar-31
ing citalopram with its “me-too”, escitalopram, which found an32
inconsistency between direct evidence (showing a superiority of33
escitalopram) and indirect evidence (which did not ﬁnd any sig-34
niﬁcant diﬀerence). [60]35
10. Poor transposability of RCT results36
Beyond these issues RCTs are often criticised for their lack of37
external validity. Indeed, the vast majority of patients with clinical38
depression are catered for in primary care, and most RCTs have39
involved secondary care patients. [61] These patients probably dif-40
fer from primary care patients. [62,63] in terms of severity (primary41
care patients are less severely depressed, milder course of illness)42
and in terms of complaints (fatigue and somatic symptoms). [64]43
Additionally, antidepressant RCTs use numerous non-inclusion44
criteria (for example suicidal ideations) [65–67] and excluded pa- 45
tients are a more chronically ill group with more numerous previ- 46
ous episodes, greater psychosocial impairment, and more frequent 47
personality disorders. Finally, the vast majority of RCTs last no 48
more than 8 weeks, whereas it is recommended that an antidepres- 49
sant treatment be continued for at least 6 months after remission 50
of the episode. [68] 51
There is debate as to whether these issues can be trans- 52
lated into diﬀerent outcomes between RCTs and a “real life” 53
setting. [69–72] 54
11. Conclusion 55
While meta-analyses should be reproducible, in 2013, a meta- 56
analysis of published and unpublished studies on agomelatine 57
found “evidence suggesting that a clinically important diﬀerence 58
between agomelatine and placebo in patients with unipolar ma- 59
jor depression was unlikely”; [73] in 2014 a meta-analysis of pub- 60
lished and unpublished studies on agomelatine found that it “was 61
an eﬀective antidepressant with similar eﬃcacy to standard an- 62
tidepressants”. [74] This particular paradox sums up the fuzziness 63
of antidepressant literature. We suggest that, instead of providing 64
easy answers, the application of the RCT paradigm to MDD raises 65
many questions. This is probably in the nature of all scientiﬁc 66
studies, but it can be in contradictionwith clinicians’ expectations: 67
what they want is to be sure that the treatment will work for indi- 68
vidual patients (or to know if it will not). At the same time, their 69
clinicial experience is biased by many other parameters, including 70
placebo response. This is precisely where the debate arises. 71
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